Tenax Phase 3 LEVEL Trial Misses Primary Endpoint, But Subgroup and Biomarker Data Show Promise
TENX is trading near its 52-week low of $5.78 (61% below the low).
Summary
Tenax Therapeutics' Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, but prespecified subgroup and biomarker analyses showed significant benefits in patients with higher disease burden, supporting a revised regulatory strategy.
Updates
· Benzinga — Shares closed down 89.49% to $1.79. Subgroup with baseline walk distance under 333 meters showed 26.3-meter benefit; NT-proBNP fell 49%.
· Dow Jones Newswires — Shares fell 85% premarket to $2.07. The company cited a $17.8M Q2 loss and $118M cash, runway to Q2 2028.
Key Events · Product Development and Regulatory · TENX
-
Primary Endpoint Missed
TNX-103 failed to show statistically significant improvement in 6-minute walk distance vs placebo (LS mean difference 3.5m, p=0.63) in the overall Phase 3 LEVEL trial population.
-
Subgroup Efficacy Signal
In a prespecified analysis of patients with baseline 6MWD below the median of 333 meters, TNX-103 showed a 26.3-meter improvement vs placebo (95% CI 6.0–46.7, nominal p=0.0112).
-
Strong Biomarker and Hemodynamic Effects
Across all patients, TNX-103 reduced NT-proBNP by 49% vs placebo (nominal p<0.0001) and lowered right ventricular systolic pressure by 3.5 mmHg (nominal p=0.0045), confirming biological activity.
-
Regulatory Path Forward
Tenax intends to request a Type C meeting with the FDA to discuss an enrichment strategy for future trials, leveraging the subgroup findings, and will seek parallel EMA scientific advice.
Analysis · TENX · Life Sciences
The Phase 3 LEVEL trial of TNX-103 in PH-HFpEF failed to meet its primary endpoint (6-minute walk distance, p=0.63) and key secondary endpoint (KCCQ-TSS). However, prespecified analyses revealed a strong treatment effect in patients with higher disease burden: those with baseline walk distance below the median of 333 meters improved by 26.3 meters versus placebo (nominal p=0.0112). Across the overall population, TNX-103 reduced NT-proBNP by 49% (nominal p<0.0001) and right ventricular systolic pressure by 3.5 mmHg (nominal p=0.0045), confirming biological activity. The company plans to request a Type C meeting with the FDA to discuss an enrichment strategy for future trials, leveraging the subgroup findings. Full results will be presented at the ESC Congress in late August. This is a critical binary event — the missed primary endpoint is a setback, but the strong biomarker and subgroup data provide a potential path forward, keeping the program alive.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 41.7% of the 300 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $2.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $503M. The 52-week trading range was $5.78 to $19.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.